Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits
- 1 October 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (10) , 1822-1823
- https://doi.org/10.1128/aac.33.10.1822
Abstract
The efficacy of cilofungin (LY121019) for aortic valve endocarditis caused by Candida albicans in rabbits was studied. Vegetation titers were similar for cilofungin-treated and untreated rabbits. No rabbit survived beyond 5 days in either group. All rabbits given amphotericin B survived, and titers were reduced. Cilofungin was ineffective in this model.This publication has 11 references indexed in Scilit:
- Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates ofCandida speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1988
- Staphylococcal endocarditis in rabbits treated with a low dose of cloxacillinAntimicrobial Agents and Chemotherapy, 1984
- In vitro and in vivo anti-Candida activity and toxicology of LY121019.The Journal of Antibiotics, 1984
- Studies on the mechanism of antifungal action of aculeacin A.The Journal of Antibiotics, 1982
- Candida albicans Endocarditis: Ultrastructural Studies of Vegetation FormationInfection and Immunity, 1978
- On the mode of action of a new antifungal antibiotic, aculeacin A: Inhibition of cell wall synthesis in Saccharomyces cerevisiae.The Journal of Antibiotics, 1977
- Tissue Penetration of Amphotericin B in Candida EndocarditisChest, 1974
- Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations.1972
- A study of experimental, staphylococcal endocarditis in dogs. I. Production of the disease, its natural history, and tissue bacteriology.1959